source
- Otsuka and Ionis report ALS drug ulefnersen meets primary endpoint in phase 3 trialOtsuka and Ionis have completed the Fusion phase 3 trial of ulefnersen, an RNA‑targeted therapy for ALS patients with mutations in the FUS gene. The study enrolled 89 participants, with 73 forming…
- Iambic Therapeutics eyes IPO as it pushes HER2 inhibitor IAM1363 into early trialsIambic Therapeutics, a San Diego AI‑driven biotech, said it is preparing for an initial public offering after securing several large‑scale partnerships with major pharmaceutical companies. In its…